Prospect Capital Yields 28%. Is This Dividend Too Good to Be True?

Prospect Capital’s share price has fallen 33.11% this year to $1.50, lifting its forward distribution yield to about 28%, while its annualized payout has been cut to $0.42 and NAV declined to $5.71 from $6.56. Its NII still covers the reduced payout on paper, but realized losses were $223.7 million for fiscal 2026 and a $264.5 million bond matures in November 2026; expected Valley Electric sale proceeds of about $281 million could help fund repayment. The article also flags FS KKR Capital’s thin distribution coverage after a temporary fee waiver and Ares Capital’s core EPS of $0.47 trailing its $0.48 quarterly dividend, while noting Ares has about $6.0 billion of liquidity.

Analysis

The key distinction is not headline yield but what has to go right to sustain it. For PSEC, proceeds from selling an asset may ease the November bond repayment while shrinking the income-producing base; if the sale does not arrest NAV losses, refinancing relief could arrive alongside weaker distribution capacity. Its move toward first-lien loans may reduce loss severity, but cannot by itself offset borrower defaults or falling loan yields. FSK has a separate near-term earnings cliff: the fee waiver masks underlying coverage, so expiry could expose a payout gap just as elevated non-accruals pressure asset marks. ARCC’s small coverage shortfall is less urgent, but still makes the dividend sensitive to incremental credit deterioration or lower floating-rate income.

Over days, PSEC’s October 28 ex-date and upcoming maturity can drive positioning and liquidity, but the ex-date is not a fundamental catalyst. Over 1–3 months, verify sale proceeds, maturity repayment/refinancing, subsequent NII and non-accrual trends, and FSK’s post-waiver earnings. Over 6–18 months, falling rates could compress BDC asset yields; funding-cost relief may lag, while weakening borrower cash flows would compound the pressure. Contrarian point: the three yields do not represent equivalent risks. A broad BDC short could miss the relative quality gap, while steep discounts to NAV may already reflect some impairment—especially where reported NAV proves conservative. Treat NAV as an estimate, not liquidation value.

Key Decisions for Investors

• Relative-value watch/trade: favor ARCC over PSEC, potentially via a dollar-neutral pair, rather than buying the highest yield. Keep exposure modest and account for dividend carry and short-sale costs. Thesis weakens if PSEC stabilizes NAV and NII/share while ARCC’s coverage or credit metrics deteriorate.
• Do not underwrite PSEC’s payout from the sale proceeds alone. Before adding, confirm the November maturity is repaid or refinanced and that the next report shows stable NII/share and NAV; a failed funding plan or further NAV decline is a thesis-falsifying downside catalyst.
• For FSK, avoid treating the current distribution as normalized earnings until results after the fee waiver show coverage without support. Track waiver terms, NII/share, non-accruals, and NAV; persistent uncovered distributions would raise cut risk, while restored coverage and improving credit marks would argue against the bearish view.
• For ARCC, monitor rather than short solely on a one-cent quarterly coverage gap. A sustained decline in core earnings, rising non-accruals, or another NAV step-down would make the gap more consequential; stable coverage and credit quality would support the view that the current pressure is manageable.